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Introduction
Background: Genome-wide association studies (GWAS) have linked human chromosome 8q24.21 region with increased risk for prostatic carcinoma but the how this region contributes to prostate carcinogenesis is unknown. In this gene desert of 1.2Mb between FAM84B and the c-MYC oncogene, POU5F1B (also called POU5F1P1) is a candidate gene with coding capacity. It is a pseudogene of embryonic Oct4 (POU5F1). A recent study found that tumor Oct4 found in prostate cancer cells is due to the gene expression of POU5F1P1 (Hugo name: POU5F1B), not embryonic Oct4 (POU5F1). Our in silico analysis found a significant increase in Oct4 (POU5F1B) in primary tumors and a marked increase in metastatic tumors, when compared to normal prostate or adjacent normal tissues. Tumor Oct4 expression was higher in tumorigenic prostate cancer cells than in non-tumorigenic RWPE-1 cells. Depletion of tumor Oct4 in prostate cancer cells reduced their tumorigenic potential. We cloned tumor Oct4 and found that increased expression of tumor Oct4 in prostate cancer cells stimulated tumor cell motility. Further a significant divergence was found between tumor Oct4 and embryonic Oct4 in regulating Wnt/-caenin signaling. It is our hypothesis that tumor Oct4, expressed from POU5F1B in the prostate cancer susceptibility loci 8q24, is a driver of prostate tumor formation and progression, and therefore, this driver is a novel target of intervention to eliminate prostate cancer.
Objective:
The objective is to determine whether tumor Oct4 promotes tumor formation and metastasis, to determine whether tumor Oct4 can be targeted to treat prostate cancer progression, and to elucidate the mechanism involved for tumor Oct4 to promote prostate carcinogenesis.
Specific Aims: 1) Investigate whether tumor Oct4 promotes prostate tumor initiation and metastasis.
2) Determine whether tumor Oct4 can be targeted to reduce prostate tumor formation, progression, and metastasis.
3) Elucidate the mechanism involved for tumor Oct4 in promoting prostate carcinogenesis.
.
BODY OF REPORT
Scientific portion: Task 1. Investigate whether tumor Oct4 promotes prostate tumor initiation and metastasis (Month 1 -18).
The overexpression of tumor POU5F1B in prostate cancer LNCaP cell lines and subsequent effects on tumor cell growth in vitro and tumor formation and growth in vivo have been described in last report. Here we describe some findings previously not reported.
POU5F1B expression in prostatic tissue
As cancer stem cell marker, OCT4 expression has been observed in many cancers, including breast cancer (Ezeh et al., 2005) , bladder cancer (Atlasi et al., 2007) , lung cancer (Karoubi et al., 2009 ) and prostate cancer (Monsef et al., 2009; Sotomayor et al., 2009; Su et al., 2004) . However, a recent conclusive study suggests that POU5F1B, not OCT4-A or OCT4-B, is expressed in prostate cancer cell lines and prostatic tissue (Kastler et al., 2010) .
To access the clinical relevance of POU5F1B in prostate carcinogenesis, we conducted in silico analysis of expression profiles in a prostate cancer progression dataset (GDS2545). The dataset were obtained from 171 samples including normal, adjacent normal, primary tumors, and metastatic tumors (From left to right, Figure 1A) . A general trend of increased POU5F1B expression was noted. Further detailed analysis of the probe intensity in the four types of tissues revealed a significant increase in POU5F1B in primary tumors and a marked increase in metastatic tumors, when compare to normal prostate or adjacent normal tissues ( Figure 1B ). It should be noted that in this dataset no POU5F1 (OCT4) expression was found. The data suggest that POU5F1B, not POU5F1 (OCT4), is responsible for prostate cancer progression. (Suo et al., 2005) . The highly homologous between OCT4 and its pseudogenes can cause false positive artifacts of OCT4 expression by RT-PCR (Liedtke et al., 2008) . By using OCT4 and POU5F1B specific RT-PCR, Kalster et al. showed it is POU5F1B, but not OCT4 is expressed in prostatic carcinoma and surrounding prostatic tissue (Kastler et al., 2010) .
We can use OCT4 antibody to detect POU5F1B in prostate cell lines. (C) Statistical analysis of POU5F1B expression in 44 prostate tumor tissues. The increased incidence of POU5F1B positive staining in higher grade prostate adenocarcinomas was noted.
Alignment of PC3 POU5F1B ORF sequence with NCBI POU5F1B sequence (NM_001159542.1)
The enzyme digestion confirmed constructs were sent for sequencing. When we aligned the sequence of insert with POU5F1B (NM_001159542.1), two mismatches was noted, CAG AG (Glutamic acid/EGlutamine/Q). The first mismatch is a silent mutation, which will not cause amino acid change. The second mismatch will cause glutamic acid to glutamine change ( Figure 3A ). These two mismatches have been reported as SNP rs6998254 and SNP rs7002225 respectively ( Figure 3B ).
When compare PC3 POU5F1B amino acid sequence with NCBI POU5F1B amino acid sequence, only one amino acid changed, E 238 in NCBI POU5F1B but Q 238 in PC3 POU5F1B. When compare POU5F1B amino acid with POU5F1, we found fifteen amino acids are different, eight of them located at N domain, two located at POU specific domain, one in linker region, one in POU homeodomain and three in C domain ( Figure 3C ). Some amino acids change may contribute to protein structure, such as R33L, from basic, positive, polar to neutral hydrophobic; G97S, hydrophobic to polar; D108N, acid, negative to neutral; T118P, polar to hydrophobic; E135K, acidic, negative to basic, positive; T170I, polar to hydrophobic; T182K, neutral to basic, positive; Q259 polar was deleted; T351I, polar to hydrophobic (Table 1) . Hans R.
Schöler showed the linker between two POU domains of mouse OCT4 is exposed to the surface of the protein and it is very important for reprogramming activity of OCT4 and protein-protein interaction (Esch et al., 2013) . To map the sequences or residues which are critical for the different function between POU5F1B and OCT4 would provide more clues for better understanding why it is POU5F1B not OCT4 is expressed in prostatic carcinoma and surrounding prostatic tissue. 
POU5F1B can promote colony formation in soft agar
The anchorage-independent growth (AIG) is an important step in acquisition of malignancy (Freedman and Shin, 1974) . Cells with anchorage-independent growth ability have the potential to migrate through the body, colonize other tissues and grow metastatically (Gassmann and Haier, 2008) . The soft agar colony formation assay is a common method to monitor anchorage-independent growth.
As showed in Figure 4 , LNCaP POU5F1B formed 75.5±7.63 colonies in soft agar, whereas in LNCaP pCDHmyc vector, the number of colonies was significantly decreased, only 26.75±7.63 (P<0.001). 
POU5F1B can induce EMT in DU145 cells
We observed the cells lost tight cell-cell adhesion when POU5F1B is overexpressed, which suggests the cells undergo EMT process. Down-regulation of E-Cadherin is one of the hallmarks of EMT. First, we assessed the cellular localization and expression of E-Cadherin in DU145 pCDH myc vector and DU145 POU5F1B cells. Immunocytochemistry staining showed typically E-Cadherin localization at cell-cell junction in pCDH myc vector cells, but such staining pattern was disapperaed in POU5F1B overexpressed cells (Figure 6 A) . Furthermore, immunoblot confirmed the down-regulation of E-Cadherin after POU5F1B overexpression ( Figure 6B ). The reductidon of E-Cadherin was not found in immortalized normal prostate epithelial cell line RWPE-1 cells with POU5F1B overxpression ( Figure 6B ). This suggest that POU5F1B decrease E-Cadherin is cell-dependent. E-Cadherin is the main component of the cell-cell adhesion junctions, loss of its expression will increase cell mitility.
To investigate other EMT-related gene expression, we did EMT-related gene microarray. As showed in We have introduced shRNA constructs into PC3MM and DU145 cells. Currently we are screening stable clones that can be used for our studies.
Task 3: Elucidate the mechanism involved for tumor Oct4 in promoting prostate carcinogenesis (Month 18 -36) .
POU5F1B and stem cell
To investigate whether POU5F1B overrxpression can induce cancer stem cell-related genes expression, we did cancer stem cell microarray. 84 cancer stem cell related genes are investigated. The functional grouping of these genes were shown in Table 2 . We observed a very prominent overexpression of cancer stem cell related genes after POU5F1B expression. In DU145 cells, nearly half of all tested genes were overexpressed by at least 2 folds in POU5F1B cells. In PC3 cells, 2 fold overexpression was observed in a quarter of tested genes. Most notably, we found 14 genes that are significantly overexpressed in both DU145 and PC3 POU5F1B cells, including essential pluripotency regulators NANOG, SOX2, and BMI; cell adhesion and migration molecules PECAM1, THY1, ITGA4; and oncogenes MYCN, cKIT, WNT1 (Figure 9 ). 
Migration & Metastasis
AXL, ID1, IL8, KLF17, PLAT, PLAUR, SNAi1, TWIST1, TWIST2, ZEB1, ZEB2. (A) Cancer stem cell genes expression profile in DU145 pCDH and DU145 POU5F1B.
Loss of Stemness
(B) Cancer stem cell genes expression profile in PC3 pCDH and PC3 POU5F1B.
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